Cladribine News and Research

RSS
Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Scientists highlight the benefits of Droplet Digital PCR technology at the 2019 ASH meeting

Scientists identify new way to target bottleneck for cancer cell growth

Scientists identify new way to target bottleneck for cancer cell growth

FDA approves new oral drug to treat relapsing forms of multiple sclerosis

FDA approves new oral drug to treat relapsing forms of multiple sclerosis

Innovative drugs and new European treatment guidelines refine, improve MS therapy

Innovative drugs and new European treatment guidelines refine, improve MS therapy

Drug blocked by regulators found to improve quality of life for MS patients

Drug blocked by regulators found to improve quality of life for MS patients

Merck presents data on investigational cladribine tablets in relapsing multiple sclerosis

Merck presents data on investigational cladribine tablets in relapsing multiple sclerosis

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

Pill for multiple sclerosis in the pipeline

Pill for multiple sclerosis in the pipeline

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Exciting progress made in MS research during 2010

Exciting progress made in MS research during 2010

FDA extends review period of Cladribine Tablets for MS therapy

FDA extends review period of Cladribine Tablets for MS therapy

Physicians anticipate new oral therapies for multiple sclerosis patients

Physicians anticipate new oral therapies for multiple sclerosis patients

Event Pulse report reveals impact of new therapies on MS drug market

Event Pulse report reveals impact of new therapies on MS drug market

FDA accepts for filing Cladribine Tablets NDA for MS

FDA accepts for filing Cladribine Tablets NDA for MS

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

New data on Cladribine Tablets presented at AAN annual meeting

New data on Cladribine Tablets presented at AAN annual meeting

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week: Time for nation to go orange and move it to end MS

EMD Serono announces results from CLARITY Phase III trial in MS patients

EMD Serono announces results from CLARITY Phase III trial in MS patients